SLS-005
Spinocerebellar Ataxia (SCA)
Key Facts
About Seelos Therapeutics
Seelos Therapeutics is a publicly traded, clinical-stage biopharmaceutical company focused on the efficient development of therapies for CNS disorders and rare diseases. Founded in 2016, its strategy centers on acquiring and developing a diversified portfolio of assets, including small molecules, psychedelics, and gene therapies, often through repurposing or reformulating known compounds. The company's lead asset, SLS-002 (intranasal racemic ketamine) for Acute Suicidal Ideation and Behavior (ASIB), is in a registration-directed Phase 2 study, representing its most advanced program. Seelos operates as a lean organization, aiming to de-risk development by targeting serious conditions with limited treatment options.
View full company profileAbout Seelos Therapeutics
Seelos Therapeutics is a publicly traded, clinical-stage biopharmaceutical company focused on the efficient development of therapies for CNS disorders and rare diseases. Founded in 2016, its strategy centers on acquiring and developing a diversified portfolio of assets, including small molecules, psychedelics, and gene therapies, often through repurposing or reformulating known compounds. The company's lead asset, SLS-002 (intranasal racemic ketamine) for Acute Suicidal Ideation and Behavior (ASIB), is in a registration-directed Phase 2 study, representing its most advanced program. Seelos operates as a lean organization, aiming to de-risk development by targeting serious conditions with limited treatment options.
View full company profileOther Spinocerebellar Ataxia (SCA) Drugs
| Drug | Company | Phase |
|---|---|---|
| Troriluzole | Biohaven | Phase 3 |